# Inozyme Pharma, Inc.

Inozyme Pharma, Inc. is a company headquartered in Boston, MA, United States.

## Company overview

- **Legal name:** Inozyme Pharma, Inc.
- **Former names in filing history:** Inozyme Pharma, LLC (2017-01-05 to 2017-01-05)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Boston, MA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001693011

## About

Inozyme Pharma, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001693011, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2025-03-10, it reported net income of USD -102,024,000; total assets of USD 123,182,000 for the fiscal period ended 2024-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2024 (period ended 2024-12-31)

- **Net income:** -$102.0M (USD -102,024,000)
- **Total assets:** $123.2M (USD 123,182,000)
- **Cash and equivalents:** $21.1M (USD 21,081,000)
- **Operating cash flow:** -$91.9M (USD -91,907,000)

### FY2023 (period ended 2023-12-31)

- **Net income:** -$71.2M (USD -71,169,000)
- **Total assets:** $200.8M (USD 200,847,000)
- **Cash and equivalents:** $34.6M (USD 34,588,000)
- **Operating cash flow:** -$70.7M (USD -70,675,000)

### FY2022 (period ended 2022-12-31)

- **Net income:** -$67.1M (USD -67,061,000)
- **Total assets:** $139.2M (USD 139,195,000)
- **Cash and equivalents:** $32.9M (USD 32,915,000)
- **Operating cash flow:** -$57.8M (USD -57,761,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

### FY2021 (period ended 2021-12-31)

- **Net income:** -$56.6M (USD -56,624,000)
- **Total assets:** $123.5M (USD 123,541,000)
- **Cash and equivalents:** $23.3M (USD 23,316,000)
- **Operating cash flow:** -$48.2M (USD -48,153,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form 8-K — filed 2025-07-01 — period 2025-07-01 — 8-K
- Form 8-K — filed 2025-06-23 — period 2025-06-20 — 8-K
- Form 8-K — filed 2025-06-02 — period 2025-05-30 — 8-K
- Form 8-K — filed 2025-05-16 — period 2025-05-16 — 8-K
- Form 10-Q — filed 2025-05-14 — period 2025-03-31 — 10-Q
- Form 8-K — filed 2025-05-14 — period 2025-05-14 — 8-K
- Form DEF 14A — filed 2025-04-29 — period 2025-04-29 — DEF 14A
- Form 10-K — filed 2025-03-10 — period 2024-12-31 — 10-K
- Form 8-K — filed 2025-03-10 — period 2025-03-07 — 8-K
- Form 8-K — filed 2025-01-10 — period 2025-01-10 — 8-K
- Form SC 13G — filed 2024-12-09 — SCHEDULE 13G
- Form SC 13G — filed 2024-11-08

---

Updated: 2026-10-23T20:12:17Z

Canonical page: https://altss.com/profile/inozyme-pharma-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology